The features and efficiency of therapy for uncomplicated cystitis in pregnant women and puerperas
Objective. To investigate the features of therapy and to evaluate its efficiency for acute uncomplicated cystitis in pregnant women and puerperas.Serov V.N., Balushkina A.A., Tyutyunnik V.L., Kan N.E.
Matetials and methods. The investigation enrolled 46 pregnant women and 10 puerperas with acute uncomplicated cystitis. All the patients underwent clinical and laboratory examination and received therapy with fosfomycin trometamol at a single 3-g dose.
Results. Fosfomycin demonstrated a significant efficacy: there was regression of clinical symptoms in 96.4% of the patients and complete pathogen elimination in 94.6%; there were no recurrent cystitis at a 3-month follow-up after therapy. Neither side effects nor adverse reactions were found; a high compliance to therapy was noted.
Conclusion. The first-line empirical treatment of acute uncomplicated cystitis in pregnant women and puerperas is single-dose fosfomycin trometamol that exceeds antibacterial drugs in a long-term dosage regimen in terms of convenience of use.
Keywords
urinary tract infections
acute cystitis
fosfomycin
pregnancy
postpartum period
References
- Kalinderi K., Delkos D., Kalinderis M., Athanasiadis A., Kalogiannidis I. Urinary tract infection during pregnancy: current concepts on a common multifaceted problem. J. Obstet. Gynaecol. 2018; 38(4): 448-53. https://dx.doi.org/10.1080/01443615.2017.1370579.
- Аляев Ю.Г., Глыбочко П.В., Пушкарь Д.Ю. Урология. Клинические рекомендации. М.: ГЭОТАР-Медиа; 2016. [Alyaev Yu.G., Glybochko P.V., Pushkar D.Yu. Urology. Clinical guidelines. M.: GEOTAR-Media; 2016. (in Russian)].
- Flores-Mireles A.L., Walker J.N., Caparon M., Hultgren S.J. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 2015; 13(5): 269-84. https://dx.doi.org/10.1038/nrmicro3432.
- Matuszkiewicz-Rowińska J., Małyszko J., Wieliczko M. Urinary tract infections in pregnancy: old and new unresolved diagnostic and therapeutic problems. Arch. Med. Sci. 2015; 11(1): 67-77. https://dx.doi.org/10.5114/aoms.2013.39202.
- Перепанова Т.С. Федеральные клинические рекомендации 2015. Антимикробная терапия и профилактика инфекций почек, мочевыводящих путей и мужских половых органов. Терапевтический архив. 2016; 88(4): 100-4. [Perepanova T.S. Federal Clinical Recommendations 2015. Antimicrobial therapy and profile of kidney, urinary tract and male genital infections. Therapeutic archive. 2016; 88 (4): 100-4. (in Russian)].
- Grabe M., Bartoletti R., Bjerklund Johansen T.E., Cai T., Çek M., Köves B. et al. Guidelines on urological infections. European Association of Urology;2015. 86 p.
- Kim H.Y., Lee S.J., Lee D.S., Yoo J.M., Choe H.S. Microbiological characteristics of unresolved acute uncomplicated cystitis. Microb. Drug Resist. 2016; 22(5): 387-91. https://dx.doi.org/10.1089/mdr.2015.0241.
- Grigoryan L., Trautner B.W., Gupta K. Diagnosis and management of urinary tract infections in the outpatient setting: a review. JAMA. 2014; 312(16): 1677-84. https://dx.doi.org/10.1001/jama.2014.12842.
- Marshall K., Hale D. Urinary tract infections. Home Healthc. Now. 2017; 35(8): 448-9. https://dx.doi.org/10.1097/NHH.0000000000000597.
- Barros B.S. Antibiotic treatment for uncomplicated urinary tract infections. JAMA. 2018; 320(12): 1284. https://dx.doi.org/10.1001/jama.2018.10011.
- Yang B., Yang F., Wang S., Wang Q., Liu Z., Feng W. et al. Analysis of the spectrum and antibiotic resistance of uropathogens in outpatients at a tertiary hospital. J. Chemother. 2018; 30(3): 145-9. https://dx.doi.org/10.1080/1120009X.2017.1418646.
- Arana D.M., Rubio M., Alós J. Evolution of antibiotic multiresistance in Escherichia coli and Klebsiella pneumoniae isolates from urinary tract infections: A 12-year analysis (2003-2014). Enferm. Infecc. Microbiol. Clin. 2017; 35(5): 293-8. https://dx.doi.org/10.1016/j.eimc.2016.02.018.
- Lee D.S., Lee S.J., Choe H.S. Community-acquired urinary tract infection by Escherichia coli in the era of antibiotic resistance. Biomed. Res. Int. 2018; 2018: 7656752. https://dx.doi.org/10.1155/2018/7656752. eCollection 2018.
- Bader M.S., Loeb M., Brooks A.A. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad. Med. 2017; 129(2): 242-58. https://dx.doi.org/10.1080/00325481.2017.1246055.
- Лисицына О.И. Фосфомицин в лечении острого неосложненного цистита. Взгляд акушера-гинеколога. Акушерство и гинекология. 2019; 2: 165-9. [Lisitsyna O.I. Fosfomycin in the treatment of acute uncomplicated cystitis. Look obstetrician-gynecologist. Akusherstvo i Ginekologiya/Obstetrics and gynecology. 2019; 2: 165-9. (in Russian)].
- Zhanel G.G., Walkty A.J., Karlowsky J.A. Fosfomycin: a first-line oral therapy for acute uncomplicated cystitis. Can. J. Infect. Dis. Med. Microbiol. 2016; 2016: 2082693. https://dx.doi.org/10.1155/2016/2082693.
- Mannucci C., Dante G., Miroddi M., Facchinetti F., D’Anna R., Santamaria A. et al. Vigilance on use of drugs, herbal products, and food supplements during pregnancy: focus on fosfomycin. J. Matern. Fetal Neonatal Med. 2019; 32(1): 125-8. https://dx.doi.org/10.1080/14767058.2017.1373761.
- Kranz J., Schmidt S., Lebert C., Schneidewind L., Mandraka F., Kunze M. et al. The 2017 Update of the German clinical guideline on epidemiology, diagnostics, therapy, prevention, and management of uncomplicated urinary tract infections in adult patients. Part II: Therapy and prevention. Urol. Int. 2018; 100(3): 271-8. https://dx.doi.org/10.1159/000487645.
- Matthews P.C., Barrett L.K., Warren S., Stoesser N., Snelling M., Scarborough M., Jones N. Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study. BMC Infect. Dis. 2016; 16(1): 556. https://dx.doi.org/10.1186/s12879-016-1888-1.
- Raz R. Fosfomycin: an old-new antibiotic. Clin. Microbiol. Infect. 2012; 18(1): 4-7. https://dx.doi.org/10.1111/j.1469-0691.2011.03636.x.
- Cho Y.H., Jung S.I., Chung H.S., Yu H.S., Hwang E.C., Kim S.O. et al. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin. Int. Urol. Nephrol. 2015; 47(7): 1059-66. https://dx.doi.org/10.1007/s11255-015-1018-9.
- Sultan A., Rizvi M., Khan F., Sami H., Shukla I., Khan H.M. Increasing antimicrobial resistance among uropathogens: is fosfomycin the answer? Urol. Ann. 2015; 7(1): 26-30. https://dx.doi.org/10.4103/0974-7796.148585.
- Rosso-Fernández C., Sojo-Dorado J., Barriga A., Lavín-Alconero L., Palacios Z., López-Hernández I. et al.; FOREST Study Group. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial. BMJ Open. 2015; 5(3): e007363. https://dx.doi.org/10.1136/bmjopen-2014-007363.
- Reffert J.L., Smith W.J. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2014; 34(8): 845-57. https://dx.doi.org/10.1002/phar.1434.
Received 09.04.2019
Accepted 19.04.2019
About the Authors
Serov, Vladimir N., MD, professor, academician of the Russian Academy of Sciences, chief researcher, National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after Academician V.I. Kulakov, Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina str. 4. Тel.: +74954387287. E.mail: v_serov@oparina4.ru. ORCID ID 0000-0003-2976-7128.Balushkina, Anna A., PhD, researcher of the National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov Ministry
of Health of Russia. 117997, Russia, Moscow, Ac. Oparina, 4 str. Tel.: +79160352471. E-mail: ann.balushkina@gmail.com. Number Researcher ID А-9582-2015.
ORCID ID 0000-0002-6342-6434.
Tyutyunnik, Victor L., MD, professor, the head of the Obstetric Physiological Department, National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina, 4 str. Tel.: +79039695041. E-mail: tioutiounnik@mail.ru.
Number Researcher ID B-2364-2015.ORCID ID 0000-0002-5830-5099
Kan, Natalia E., MD, professor, Department of Obstetrics and Gynecology, National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov of the Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina, 4 str. Tel.: +79262208655. E-mail: kan-med@mail.ru.
Number Researcher ID B-2370-2015. ORCID ID 0000-0001-5087-5946.
For citations: Serov V.N., Balushkina A.A., Tyutyunnik V.L., Kan N.E. Umbilical cord blood acid-base balance and gas composition in relation to the use of epidural analgesia in vaginal delivery. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2019; (5): 120-4. (in Russian)
http://dx.doi.org/10.18565/aig.2019.5.120-124
Similar Articles
